Join Bio-Techne's Upcoming Financial Results Conference Call

Bio-Techne Corporation to Host Financial Results Call
Bio-Techne Corporation (NASDAQ: TECH) has officially announced that its management will conduct a conference call and webcast. This call is scheduled to take place on Wednesday, May 7, 2025, at 8:00 a.m. CDT, where the company will review its financial results for the third quarter of fiscal 2025.
How to Join the Discussion
Those interested in participating in the conference call can join via the following details:
Call Details
Time: 8:00 a.m. CDT
Date: May 7, 2025
Dial-in: 1-877-407-9208 (U.S.) or 1-201-493-6784 (international)
Conference ID: 13753150
Participants who cannot join the live event can access a recorded rebroadcast. For this, dial 1-844-512-2921 or 1-412-317-6671 (for international callers) using Conference ID 13753150. The replay will be available starting from 11:00 a.m. CDT on the same day until 11:00 p.m. CDT on June 7, 2025.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a leading global life sciences company, known for its innovative tools and bioactive reagents tailored for the research and clinical diagnostic sectors. The organization's wide array of products supports scientific inquiry into biological processes while facilitating drug discovery and providing the resources essential for precise clinical testing and diagnosis.
In the prior fiscal year, Bio-Techne generated around $1.2 billion in net sales, showcasing its substantial market presence and robust operational capabilities with approximately 3,100 employees scattered across the globe.
For those curious about the company's vast offerings, it boasts an impressive catalog filled with hundreds of thousands of products. As a reputable name in the field, Bio-Techne remains committed to enhancing the scientific community's research endeavors.
Connect with Bio-Techne
To discover more about Bio-Techne and its products, follow the company on its various social media platforms to stay updated on the latest innovations and offerings. Their digital presence includes platforms such as Facebook, LinkedIn, Twitter, and YouTube.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call will address the financial results for Bio-Techne's third quarter of fiscal 2025, providing insights into the company's performance.
How can I participate in the conference call?
Interested participants can join the call using the provided dial-in numbers and conference ID. A recorded version will also be available for later listening.
When will the financial results be discussed?
The financial results will be discussed on May 7, 2025, at 8:00 a.m. CDT.
Who should I contact for more information?
David Clair, Vice President of Investor Relations & Corporate Development, is the primary contact for inquiries regarding the conference call.
Where can I find more information about Bio-Techne's products?
More information is available on the Bio-Techne website and through their social media channels, where they share updates and insights on their offerings.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.